Literature DB >> 30576442

Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer.

Stacey J Winham1, Nicholas B Larson1, Sebastian M Armasu1, Zachary C Fogarty1, Melissa C Larson1, Brian M McCauley1, Chen Wang1, Kate Lawrenson2,3, Simon Gayther3, Julie M Cunningham4, Brooke L Fridley5, Ellen L Goode6.   

Abstract

X chromosome inactivation (XCI) is a key epigenetic gene expression regulatory process, which may play a role in women's cancer. In particular tissues, some genes are known to escape XCI, yet patterns of XCI in ovarian cancer (OC) and their clinical associations are largely unknown. To examine XCI in OC, we integrated germline genotype with tumor copy number, gene expression and DNA methylation information from 99 OC patients. Approximately 10% of genes showed different XCI status (either escaping or being subject to XCI) compared with the studies of other tissues. Many of these genes are known oncogenes or tumor suppressors (e.g. DDX3X, TRAPPC2 and TCEANC). We also observed strong association between cis promoter DNA methylation and allele-specific expression imbalance (P = 2.0 × 10-10). Cluster analyses of the integrated data identified two molecular subgroups of OC patients representing those with regulated (N = 47) and dysregulated (N = 52) XCI. This XCI cluster membership was associated with expression of X inactive specific transcript (P = 0.002), a known driver of XCI, as well as age, grade, stage, tumor histology and extent of residual disease following surgical debulking. Patients with dysregulated XCI (N = 52) had shorter time to recurrence (HR = 2.34, P = 0.001) and overall survival time (HR = 1.87, P = 0.02) than those with regulated XCI, although results were attenuated after covariate adjustment. Similar findings were observed when restricted to high-grade serous tumors. We found evidence of a unique OC XCI profile, suggesting that XCI may play an important role in OC biology. Additional studies to examine somatic changes with paired tumor-normal tissue are needed.
© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30576442      PMCID: PMC6625007          DOI: 10.1093/hmg/ddy444

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  74 in total

1.  Chromosomes, sex chromatin, and cancer.

Authors:  M L BARR; K L MOORE
Journal:  Proc Can Cancer Conf       Date:  1957

2.  An apparent excess of sex- and reproduction-related genes on the human X chromosome.

Authors:  G M Saifi; H S Chandra
Journal:  Proc Biol Sci       Date:  1999-01-22       Impact factor: 5.349

3.  A first-generation X-inactivation profile of the human X chromosome.

Authors:  L Carrel; A A Cottle; K C Goglin; H F Willard
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

4.  The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome.

Authors:  Yoshiyuki Seki; Mary Ann Suico; Ayako Uto; Akinobu Hisatsune; Tsuyoshi Shuto; Yoichiro Isohama; Hirofumi Kai
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

5.  Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.

Authors:  R E Buller; A K Sood; T Lallas; T Buekers; J S Skilling
Journal:  J Natl Cancer Inst       Date:  1999-02-17       Impact factor: 13.506

Review 6.  Mammalian ABC transporters in health and disease.

Authors:  P Borst; R Oude Elferink
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

7.  Survival among U.S. women with invasive epithelial ovarian cancer.

Authors:  Valerie McGuire; Christine A Jesser; Alice S Whittemore
Journal:  Gynecol Oncol       Date:  2002-03       Impact factor: 5.482

8.  Frequent silencing of the GPC3 gene in ovarian cancer cell lines.

Authors:  H Lin; R Huber; D Schlessinger; P J Morin
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

Review 9.  Novel perspective: focusing on the X chromosome in reproductive cancers.

Authors:  Dezhong Joshua Liao; Qian-qian Du; Bennett W Yu; David Grignon; Fazlul H Sarkar
Journal:  Cancer Invest       Date:  2003       Impact factor: 2.176

Review 10.  The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction.

Authors:  Matthias A Hediger; Michael F Romero; Ji-Bin Peng; Andreas Rolfs; Hitomi Takanaga; Elspeth A Bruford
Journal:  Pflugers Arch       Date:  2003-11-18       Impact factor: 3.657

View more
  8 in total

1.  Variability of cross-tissue X-chromosome inactivation characterizes timing of human embryonic lineage specification events.

Authors:  Jonathan M Werner; Sara Ballouz; John Hover; Jesse Gillis
Journal:  Dev Cell       Date:  2022-07-31       Impact factor: 13.417

Review 2.  trans-Acting Factors and cis Elements Involved in the Human Inactive X Chromosome Organization and Compaction.

Authors:  Zhuo Sun; Jinbo Fan; Yufeng Zhao
Journal:  Genet Res (Camb)       Date:  2021-05-07       Impact factor: 1.588

3.  Interrogation of gender disparity uncovers androgen receptor as the transcriptional activator for oncogenic miR-125b in gastric cancer.

Authors:  Ben Liu; Meng Zhou; Xiangchun Li; Xining Zhang; Qinghua Wang; Luyang Liu; Meng Yang; Da Yang; Yan Guo; Qiang Zhang; Hong Zheng; Qiong Wang; Lian Li; Xinlei Chu; Wei Wang; Haixin Li; Fengju Song; Yuan Pan; Wei Zhang; Kexin Chen
Journal:  Cell Death Dis       Date:  2021-05-04       Impact factor: 8.469

4.  Germline Variants in Cancer Genes from Young Breast Cancer Mexican Patients.

Authors:  Liliana Gómez-Flores-Ramos; Angélica Leticia Barraza-Arellano; Alejandro Mohar; Miguel Trujillo-Martínez; Lizbeth Grimaldo; Rocío Ortiz-Lopez; Víctor Treviño
Journal:  Cancers (Basel)       Date:  2022-03-24       Impact factor: 6.639

Review 5.  X-Chromosome Inactivation and Related Diseases.

Authors:  Zhuo Sun; Jinbo Fan; Yang Wang
Journal:  Genet Res (Camb)       Date:  2022-03-27       Impact factor: 1.588

Review 6.  Improving clinical outcomes through attention to sex and hormones in research.

Authors:  Michelle M Mielke; Virginia M Miller
Journal:  Nat Rev Endocrinol       Date:  2021-07-27       Impact factor: 47.564

7.  Transmission of X-linked Ovarian Cancer: Characterization and Implications.

Authors:  John Lewis Etter; Kirsten Moysich; Shaun Kohli; Shashikant Lele; Kunle Odunsi; Kevin H Eng
Journal:  Diagnostics (Basel)       Date:  2020-02-07

8.  ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway.

Authors:  Yun Lin; Chun Li; Wei Xiong; Liping Fan; Hongchao Pan; Yaochen Li
Journal:  Cell Death Dis       Date:  2021-11-02       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.